

UNIVERSITI TEKNOLOGI MARA

**INTRANASAL ROUTE USING
NOVEL POLYMERIC
NANOPARTICLES AS POSSIBLE
DELIVERY STRATEGY OF DRUGS
TO ALLEVIATE ALZHEIMER'S
DISEASE**

MARISTA BINTI ABD RAZAK

Thesis submitted in fulfillment
of the requirements for the degree of
Doctor of Philosophy
(Neuroscience)

Faculty of Pharmacy

April 2019

ABSTRACT

Memantine (MEM) is a NMDA receptor antagonist that has been demonstrated to be effective in the treatment of patients with Alzheimer's disease (AD) does not cross the blood brain barrier (BBB) readily. This work attempted to improve the brain targeting efficiency of MEM by encapsulating the drug in the novel cross linked itaconic acid-n-vinylcaprolactam-polyethylene glycol (INP) nanoparticles. A novel INP nanoparticle as a carrier for MEM was formulated using the aqueous dispersion polymerization method (ADP). MEM was loaded in the polymer nanoparticles by remote loading method. MEM loaded polymeric nanoparticles were characterized by Fourier transform infrared spectroscopy (FTIR), wide angle X-ray diffraction (WAXD), differential scanning calorimetry (DSC), scanning electron microscopy (SEM) and transmission electron microscopy (TEM). Particles size and surface charge on the polymeric nanoparticles were evaluated by Zetasizer. WAXD analysis revealed an amorphous nature of the blend polymeric nanoparticles; probably due to the increased composition of itaconic acid (IA). MEM was completely dispersed at the molecular level in the polymer nanoparticles. The blank nanoparticles showed uniform spherical nanoparticles with size ranging from 80 - 180 nm. The *in vitro* release studies on MEM loaded INP nanoparticles was conducted in phosphate buffered saline (PBS). Analysis was performed with high performance liquid chromatography mass spectrometer (LCMS) coupled to an Agilent 6410 triple quadruple mass spectrometer with an electrospray ionization source. MEM was analysed using a C18 column with an isocratic mobile phase of methanol and water, both acidified with 0.01% formic acid at a flow rate of 0.3 ml/min. The instrument was set to multi-reaction monitoring (MRM) mode using precursor and product ions of 180 and m/z 163 for quantification and confirmation respectively. Quantification was done using external calibrations. The external standard method of calibration was evaluated taking at least eight standard solutions. Calibration curves were obtained by plotting peak areas against concentrations of MEM injected. Cytotoxicity studies conducted on INP-NVC MEM 2 utilizing RPMI 2650 cell line showed no effect on the viability of the cells. *In vitro* studies were conducted utilizing different combination of polymer to incorporate MEM. The *in vitro* drug release profile of INP-NVC MEM 2 was found to be the most efficient and exhibited a biphasic release pattern with an initial burst followed by a sustained release process and utilised in the *in vivo* studies. This release pattern is crucial for drug targeting to the brain where the NPs will degrade and release the drug over a period of time to maintain the optimum therapeutic level. *In vivo* studies conducted in the brain homogenate and plasma of rats indicated that the MEM loaded INP NPs administered intranasal produced a higher drug content (DC) & encapsulation efficiency (EE) as compared to MEM solution administered via the same route or intravenously. Collectively the studies suggested the novel formulation to be effective in delivering the drug to the brain when given intranasal.

ACKNOWLEDGEMENT

Foremost, I would like to express my sincere gratitude to my supervisor Prof. Dato Dr. Abu Bakar Majeed for the continuous support of my PhD study and research, for his patience, motivation, enthusiasm, and immense knowledge. His guidance helped me in all the time of research and writing of this thesis. My sincere most thanks also goes to my co-supervisor Dr. Tommy Julianto Bustami Effendi for his interest and encouragement in this work and his availability to discuss issues from the beginning till the end of this research.

My gratitude also goes to the technical and administration staff of the Faculty of Pharmacy for providing all the necessary support as and when I needed it. I thank my fellow lab-mates in in the Brain Research Lab (BRL) and Biopharmaceutical & Pharmacokinetics Lab for the stimulating discussions, ideas and for being there when I needed help. I am deeply thankful to my family especially my parents, despite all the constraints for their love, support, and sacrifices from the time they bore me and making me what I am today. I must also express my sincere thanks to Mastura for her assistance in graphics.

This last word of acknowledgment I have saved for my dear husband, who stood by me through all my travails, my fits of pique and impatience and for being with me all these years and has made them the best years of my life.

TABLE OF CONTENTS

	Page
CONFIRMATION BY PANEL OF EXAMINERS	ii
AUTHOR'S DECLARATION	iii
ABSTRACT	iv
ACKNOWLEDGEMENT	v
TABLE OF CONTENTS	vi
LIST OF TABLES	xiii
LIST OF FIGURES	xvi
LIST OF SYMBOLS	xxi
LIST OF ABBREVIATIONS	xxiv
CHAPTER ONE: INTRODUCTION	1
1.1 Research Background	1
1.2 Problem Statement	4
1.3 Objectives	4
1.4 Significance of Study	5
CHAPTER TWO: LITERATURE REVIEW	6
2.1 Alzheimer's Disease	6
2.1.1 Therapy of Alzheimer's Disease	8
2.1.2 Memantine for Treatment of Alzheimer's Disease	9
2.2 Introduction to Blood Brain Barrier	10
2.3 Pharmacological Importance	12
2.4 Transport Routes Across the Blood Brain Barrier	14
2.5 Modern Methods of Transporting Drugs Across the Blood Brain Barrier	16
2.5.1 Drug Transport Across the Blood Brain Barrier Via Tight Junction	16
2.5.2 Transport System-Mediated Drug Delivery Across the Blood Brain Barrier	16
2.5.3 Drug Transport Across the Blood Brain Barrier via Transport Vectors	17

2.5.4	Drug Transport Across the Blood Brain Barrier via Adsorptive-Mediated Transcytosis	17
2.5.5	Drug Transport Across the Blood-Brain Barrier via Endogenous Receptor-Mediated Transcytosis	18
2.6	Different Routes of Administration and Drug Delivery System Used for Delivery of Drugs Across the Blood Brain Barrier	18
2.7	Nanoparticles	19
2.7.1	Nanocarriers as Drug Delivery Systems Across the Blood Brain Barrier	21
2.8	Selection of Route of Administration	21
2.8.1	Advantages of Nasal Drug Delivery System	22
2.8.2	Delivery of Drugs to the Brain by the Nasal Route	22
2.9	Anatomy of the Nasal Cavity	23
2.9.1	Transport Pathways Facilitating the Delivery of Drugs From the Olfactory Region to the CNS	24
2.9.1.1	Intracellular Transport Pathway	24
2.9.1.2	Extracellular Pathways	25
2.10	Intranasal Delivery of Therapeutic Macromolecules	25
2.10.1	Intranasal Delivery of Neuroprotective Agents Using Nanoparticles	26
2.10.2	Factors Affecting Nasal Drug Delivery to the Brain	27
2.10.2.1	Barriers to Nasal Absorption	27
2.11	Formulation Ingredients	28
2.11.1	Polymers	28
2.11.1.1	Poly (N-Vinylcaprolactam)	28
2.11.1.2	Polyethylene Glycol	31
2.11.1.3	Chitosan	33
2.11.1.4	Itaconic Acid	40
2.11.2	Cross Linking Agent	41
2.11.2.1	Ethylene Glycol Dimethacrylate	41
2.11.3	Surfactant	42
2.11.3.1	Sodium Dodecyl Sulfate	42
2.11.4	Initiator	43
2.11.4.1	Sodium Persulfate	43